Sam, the question is: how far will AEF let her run?
If ANP is partnering for P2B in Europe, then no CR required this year....and AEF irrelevant, but you never know.
Fair value compared to US peers is upward of 30c.
DMD market worth +$4B
Inflammation market worth +$100B
If they do partner, striking a "fair" valuation would be an interesting exercise.
Roche paid $1B for Sareptas gene tech IP.
Chart, page-1849
-
- There are more pages in this discussion • 4,057 more messages in this thread...
You’re viewing a single post only. To view the entire thread just sign in or Join Now (FREE)
